StemCell Therapy

When I was looking for universities to apply for an undergraduate programme, I heard about Rabindranath Tagore University (RNTU) and decided to visit the campus. I was astonished to see all the facilities offered here. Since the educational institutions in and around Vidisha dont offer similar facilities, I moved to Bhopal to join RNTU for a programme in Biotechnology.

This subject is used in different fields, including agriculture, environment and medicine and is slowly gaining popularity in India, especially in relation to agriculture, organic crops as well as cross breeding.

Infrastructure

At RNTU, we have access to excellent labs and equipment required for research, such as an in-house DNA fingerprinting lab and this makes the educational experience really engrossing.

Also, the teachers are supportive and helpful in creating an interactive learning experience. Presentations and audiovisual lessons and use of technology make the classes compelling.

The exposure to practical learning, as well as extracurricular activities, has improved my management and leadership skills. It has enabled me come out of my shell and explore the world as well as my own capabilities. One of my best experiences was representing my university at a national level debate competition organised by the Amity University, Lucknow.

In addition to participating in competitions, I was also a part of the volunteering committee at Vishwa Rang, the Tagore International Literature and Arts Festival during which I met and interacted with many artists and writers.

I was also a member of the organising team for the annual college festival Rhythm. We decided each act, divided the responsibilities and mapped of various activities with deadlines proper execution.

Even during the lockdown, we are constantly getting various internship opportunities so that our future is not adversely affected by the pandemic.

Kanika Soni is a third-year undergraduate student of Biotechnology from the Rabindranath Tagore University, Bhopal

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

View original post here:
Biotech and beyond - The Hindu

One of the biggest winners among coronavirus stocks in 2020 has been Vir Biotechnology(NASDAQ:VIR). The company's shares have more than doubled in the span of one year, turning a $10,000 investment from last September into about $22,700 today. That substantially outperformed the S&P 500, which gained 15% over the same period.

But sometimes, the higher you climb, the harder you fall. Recent controversy surrounding the company's progress with its COVID-19 programs caused the stock to fall more than 40% from its peak in late August. Should investors expect this company and its stock to rebound? Let's take a look at whether buying Vir on the dip is a golden opportunity or whether the company's drug pipeline spells trouble for its future.

Image Source: Getty Images.

Vir has two antibody treatments and a small interfering RNA (siRNA) treatment against COVID-19 in its pipeline. siRNA therapeutic candidates are based on tiny double-stranded RNA sequences coded to destroy genetic material responsible for a virus' protein synthesis, rendering it unable to replicate. The RNA treatment is undergoing preclinical studies, the results from which are expected by the end of the year. Meanwhile, one of the company's antibodies, VIR-7832, will enter phase 2 clinical trials in the fourth quarter, while the other, VIR-7831, is in phase 2/3 clinical trials. The latter candidate could made available first under an early access program like an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in the early months of 2021, if trial results are positive.

Vir has partnered with GlaxoSmithKline(NYSE:GSK) to develop its COVID-19 programs. The company is responsible for research and development (R&D) costs while GlaxoSmithKline is handling commercialization costs. Under the agreement, 72.5% of costs and profits go to Vir while the remaining 27.5% are GlaxoSmithKline's.

Without a doubt, Vir's pipeline has potential. However, there are already coronavirus treatments on the market, including Gilead Sciences'(NASDAQ:GILD) antiviral, remdesivir, and the generic steroid, dexamethasone. What's more, large-cap biotechs such as Moderna(NASDAQ:MRNA) andPfizer(NYSE:PFE) are already far along in their efforts to develop coronavirus vaccines. In fact, a vaccine could be available as soon as October. While there are no guarantees that any one of the vaccine candidates in particular will prove effective against COVID-19, it is likely that by 2022, the need for coronavirus treatments will have significantly diminished as people around the world are (hopefully) inoculated.

The company's hepatitis B pipeline is facing similar problems. Even though its treatment candidates for the disease are well into phase 2 trials, the question of their commercial feasibility is a key concern. There are already a number of effective hepatitis B vaccines available worldwide, meaning that the need for a treatment is limited to those who don't get immunized (or those whose immunizations are ineffective) and subsequently contract the virus. While 257 million people are currently living with hepatitis B, many are in developing nations and may not have the purchasing power to afford a pricey treatment course.

If that wasn't enough, Arrowhead Pharmaceuticals (NASDAQ:ARWR) andJohnson & Johnson (NYSE:JNJ) are also on their way to developing a treatment for hepatitis B. Clinical data for their candidate has looked solid. Whatever comes out of Vir's pipeline would have to compete with both existing standard-of-care treatments such as Entecavir and Tenofovir and new ones from other biotechs. This would significantly affect the company's pricing power in the event of its drug's approval.

Vir only brought in $67 million in combined licensing plus collaboration revenues in the past quarter. But currently, it has about $552.4 million in cash and investments, is operating at a net loss of $31.2 million per quarter, and has a $4.05 billion market cap. So in terms of its ability to keep moving forward with research and development, Vir's financial position is fair.

However, I don't think its shaky pipeline can justify its stock price, even after a recent decline. The market opportunities for hepatitis B and COVID-19 treatment candidates are too unstable and full of heavyweight pharma competitors. Buying Vir Biotechnology now could be like catching a falling knife. Investors looking at coronavirus stocks may wish to consider other opportunities.

Link:
Should You Buy Vir Biotechnology Stock on the Dip? - Motley Fool

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

- UBX1325 to enter clinical development in patients with diabetic macular edema -

SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it has initiated a restructuring to align its resources on cellular senescence programs in ophthalmology and neurology while further extending operating capital. UNITY will advance UBX1325 to Phase 1 clinical development in patients with diabetic macular edema, and expects to dose the first patient in the second half of 2020, consistent with prior guidance.

UNITY has prioritized its portfolio and aligned resources to deliver on key development milestones and drive innovation:

UBX1325 targets Bcl-xL, a novel mechanism to eliminate senescent cells in age-related diseases of the eye. The UBX1325 Phase 1 study in diabetic macular edema is expected to begin before the end of the year. UBX1967 remains in the portfolio as a molecularly distinct backup to UBX1325.

UNITYs neurology programs will target core features of neurodegenerative diseases. These programs build upon UNITYs foundational cellular senescence research platform and will focus on senolytic therapies for neurological diseases as well as exploring novel mechanisms for cognitive benefit.

UNITYs research programs will explore therapeutic modalities beyond small molecule approaches to significantly expand the target space for modulating senescent cell biology implicated as drivers of diseases of aging.

Revised Financial Guidance

UNITY will reduce its workforce by approximately 30% to optimize capital allocation and align with key strategic priorities, resulting in an estimated 75 full-time employees by the end of the year. These steps to focus resources are expected to extend the cash runway through mid-2022, with current cash and cash equivalents projected to fund UNITY through key clinical data readouts for UBX1325 and IND-enabling studies for UBX1967.

Story continues

"UNITY is a pioneer in the development of therapeutics targeting senescent cells at the crux of many age-related diseases, and we will continue to build on this scientific foundation as we advance our pipeline," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "At UNITY, we have an extraordinary team that has contributed greatly to the advancement of this field, and we are deeply grateful for the contributions that all of our employees have made. Moving forward we will have a leaner and more agile team, which is well-resourced to advance our pipeline programs to key milestones."

Dr. Ghosh added: We are excited about advancing UNITYs lead ophthalmology program, UBX1325, into clinical studies in patients with diabetic macular edema, an indication with a well-defined development path and objective endpoints. In addition, I see significant opportunities emerging from programs in our preclinical pipeline targeting ophthalmologic and neurologic disease. I look forward to using my experience leading drug discovery and development programs in these areas to advance the development of a new class of high efficacy therapies.

About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to UNITYs understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to extend healthspan, including for ophthalmologic and neurologic disease, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for diabetic macular edema and other ophthalmological diseases, the expected timing of initial results of the Phase 1 study of UBX1325 in diabetic macular edema, the expected size of UNITYs workforce following the restructuring, the impact of the workforce reduction on UNITYs business, and UNITYs expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITYs most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Read the original here:
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology - Yahoo Finance

Latest Research Report: Piceatannol industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Piceatannol Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/148723

Piceatannol Market competition by top manufacturers as follow:Shaanxi Fuheng (FH) BiotechnologyXian Lyphar BiotechXian Finesky TechnologicalXa Bc-BiotechXian Huisun Bio-TechRiotto BotanicalXian Biof Bio-Technology

The risingtechnology in Piceatannolmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Industrial GradePharmaceutical Grade

Market Segment by Applications, covers:DrugsCosmeticsOthers

The research report summarizes companies from different industries. This Piceatannol Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Piceatannol is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/148723

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Piceatannol-Market-148723

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Originally posted here:
Piceatannol Market Incredible Possibilities, Growth Analysis and Forecast To 2025 | Shaanxi Fuheng (FH) Biotechnology, Xian Lyphar Biotech, Xian...

Plant Biotechnology Equipment Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025The study of Plant Biotechnology Equipment market is a compilation of the market of Plant Biotechnology Equipment broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Plant Biotechnology Equipment industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Plant Biotechnology Equipment industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Request a sample of Plant Biotechnology Equipment Market report @ https://hongchunresearch.com/request-a-sample/60575

The following manufacturers are covered:Keygene(Netherlands)Heinz Walz GmbH (Germany)LemnaTec(Germany)Photon Systems Instruments(Czech Republic)Qubit Systems (Canada)Thermo Fisher Scientific (US)Tecan Group (Switzerland)LabRepCo (US)Geneq (Canada)Illumina (US)LGC Limited (UK)Evogene (Israel)

Access this report Plant Biotechnology Equipment Market @ https://hongchunresearch.com/report/worldwide-plant-biotechnology-equipment-market-2019-60575

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeSensors ModulesImaging DevicesAutomated SystemDronesLED LightingPortable Devices

Segment by ApplicationPlant ResearchBreedingProduct DevelopmentQuality AssessmentOthers

For a global outreach, the Plant Biotechnology Equipment study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Plant Biotechnology Equipment Market @ https://hongchunresearch.com/check-discount/60575

Major Point of TOC:

Chapter One: Plant Biotechnology Equipment Market Overview

Chapter Two: Global Plant Biotechnology Equipment Market Competition by Manufacturers

Chapter Three: Global Plant Biotechnology Equipment Production Market Share by Regions

Chapter Four: Global Plant Biotechnology Equipment Consumption by Regions

Chapter Five: Global Plant Biotechnology Equipment Production, Revenue, Price Trend by Type

Chapter Six: Global Plant Biotechnology Equipment Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Plant Biotechnology Equipment Business

Chapter Eight: Plant Biotechnology Equipment Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Plant Biotechnology Equipment Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Link:
Impact Of Covid-19 on Plant Biotechnology Equipment Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - The Daily...

Executive summary:

The latest report on Biotechnology Separation Systems market strives to provide a conclusive overview of the current and future market scenario with respect to the key growth catalysts, challenges, and opportunities across the various geographies.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

The Biotechnology Separation Systems market is projected to expand with a CAGR of XX% during the forecast period 2020-2025.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

In addition to region wise-assessment, the study also draws attention towards the competitive landscape by profiling the top contenders in the industry. A complete analysis of the various market segmentation is underlined in the report. Additionally, a detailed visualization of the global Covid-19 impact on the growth matrix of this business space is provided.

Market synopsis:

Regional outlook:

Product terrain outline:

Application spectrum overview:

Competitive landscape review:

Additional information from the Biotechnology Separation Systems market report:

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Market segmentation

The Biotechnology Separation Systems market is split by Type and by Application. For the period 2020-2025, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Research Objective:

Why to Select This Report:

The research process begins with internal and external sources to obtain qualitative and quantitative information related to the Biotechnology Separation Systems market. It also provides an overview and forecast for the Biotechnology Separation Systems market based on all the segmentation provided for the global region. The predictions highlighted in the Biotechnology Separation Systems market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Biotechnology Separation Systems market.

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/6449

Read the rest here:
Biotechnology Separation Systems Market Analysis, Revenue, Share, Growth Rate & Forecast To 2025 - The Research Process

REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a second lifesaving organ, human kidneys. United Therapeutics paid CollPlant $3 million for the option exercise.

The collaboration agreement combines CollPlant's proprietary recombinant human collagen (rhCollagen) and BioInk technology with the regenerative medicine and organ manufacturing capabilities of United Therapeutics.

The option exercise grants United Therapeutics through its wholly owned organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, an exclusive license to CollPlant's technology for the production and use of rhCollagen-based BioInk for 3D bioprinting of human kidneys. This expanded collaboration is aimed at helping reduce global organ shortages and thereby potentially saving lives of millions of patients on kidney waiting lists.

"Organ shortages are an unmet global health need and by partnering with United Therapeutics for the past couple of years, we have made significant progress with this pivotal organ manufacturing initiative," stated Yehiel Tal, the Chief Executive Officer of CollPlant. "United Therapeutics is pioneering the emerging organ manufacturing field, and we are honored to be part of this effort via this partnership. This option exercise demonstrates another important validation of our rhCollagen platform technology, performing as an optimal building block for regenerative medicine. We remain committed to exploring new innovative applications in the fields of medical aesthetics and 3D bioprinting of tissues and organs."

"We are excited to expand our collaboration with CollPlant's extraordinary technology to transform the tobacco plant one that is so associated with devastating diseases into a collagen-expressing plant that will be essential to the production of an unlimited number of transplantable organs," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "Our collagen-expressing plants are already flourishing in Texas where we enjoy three growing seasons."

The collaboration agreement itself, which was signed in October 2018, granted United Therapeutics an exclusive license to CollPlant's technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants. CollPlant will manufacture and supply BioInk for a few years to meet development process demand and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.

Under financial terms of the original collaboration agreement, CollPlant received an upfront payment of $5 million and will receive milestone payments of up to $15 million based on the achievement of certain operational and regulatory milestones related to the development of manufactured lungs. The agreement also provides United Therapeutics with an option to extend the license to two remaining additional life-saving organs with option exercise payments of up to $6 million. As a result of the option exercise for human kidneys these options have been extended for an additional one year through November 9, 2021. The agreement also provides additional developmental milestone payments of up to $15 million if United Therapeutics elects to develop manufactured organs other than lungs using CollPlant's technology. CollPlant will also be entitled to royalties on sales of commercialized products covered by patents licensed from CollPlant.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. CollPlant's products are based on its rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

CollPlant's products address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

CollPlant's flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, CollPlant entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

In January 2020, CollPlant entered into a Joint Development Agreement with 3D Systems Corporation, or 3D Systems, pursuant to which CollPlant and 3D Systems jointly develop tissue and scaffold bioprinting processes for third party collaborators. CollPlant's industry collaboration also includes the Advanced Regenerative Manufacturing Institute, or ARMI.

For more information, visit http://www.collplant.com.

About United Therapeutics Corporation

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens having a positive impact on patients, the environment, and society will sustain our success in the long term.

Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Safe Harbor for Forward-Looking Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's and United Therapeutics' objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant and United Therapeutics each intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's and United Therapeutics' actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the CollPlant's history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; CollPlant's and United Therapeutics' expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen-based BioInk; the CollPlant's and United Therapeutics' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based BioInk, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the CollPlant's rhCollagen-based BioInk and United Therapeutics' manufactured organs; CollPlant's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third-party distributors and resellers; CollPlant's and United Therapeutics' ability to establish and maintain strategic partnerships and other corporate collaborations; CollPlant's and United Therapeutics' reliance on third parties to conduct some aspects of its product manufacturing; the scope of protection CollPlant and United Therapeutics are able to establish and maintain for intellectual property rights and the companies' ability to operate their business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the companies operate; projected capital expenditures and liquidity; changes in the companies' strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant and United Therapeutics is contained under the heading "Risk Factors" included in CollPlant's and United Therapeutics' most recent annual report on Form 20-F and Form 10-K, respectively, filed with the SEC, and in other filings that CollPlant and United Therapeutics have made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's and United Therapeutics' current views with respect to future events, and neither company undertakes, and each company specifically disclaims, any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts at CollPlant:Eran RotemDeputy CEO & Chief Financial OfficerTel: + 972-73-2325600/612Email: Eran@collplant.com

Sophia Ononye-Onyia, PhD MPH MBAFounder & CEO, The Sophia Consulting FirmTel: +1-347-851-8641E-mail: sophia@sophiaconsultingfirm.com

Contact at United Therapeutics:Dewey SteadmanHead of Investor RelationsTel: + 1 (202) 919-4097Email: ir@unither.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/collplant-and-united-therapeutics-announce-exercise-of-option-that-will-expand-their-collaboration-to-include-3d-bioprinting-of-human-kidneys-for-transplant-301134527.html

SOURCE CollPlant; United Therapeutics Corporation

Company Codes: NASDAQ-NMS:CLGN, ISIN:IL0004960188, RICS:CLPT.TA, RICS:CQPTY, NASDAQ-NMS:UTHR

The rest is here:
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for...

PDS Biotechnology Corporation [NASDAQ: PDSB] price surged by 10.98 percent to reach at $0.28. The company report on September 8, 2020 that PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences.

PDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16th and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23rd.

H.C. Wainwright & Co. 22nd Annual Global Investment Conference:Date: Wednesday, September 16th, 2020Location: https://wsw.com/webcast/hcw7/pdsb/1599649Time: 2:30 PM ET.

A sum of 1192998 shares traded at recent session while its average daily volume was at 1.90M shares. PDS Biotechnology Corporation shares reached a high of $2.85 and dropped to a low of $2.45 until finishing in the latest session at $2.83.

The average equity rating for PDSB stock is currently 2.20, trading closer to a bullish pattern in the stock market.

Alliance Global Partners have made an estimate for PDS Biotechnology Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 27, 2020. While these analysts kept the previous recommendation, Noble Capital Markets raised their target price to Outperform. The new note on the price target was released on March 09, 2020, representing the official price target for PDS Biotechnology Corporation stock. Previously, the target price had yet another raise to $10, while Chardan Capital Markets analysts kept a Buy rating on PDSB stock.

The Average True Range (ATR) for PDS Biotechnology Corporation is set at 0.22 The Price to Book ratio for the last quarter was 2.55, with the Price to Cash per share for the same quarter was set at 0.88.

PDS Biotechnology Corporation [PDSB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.02. With this latest performance, PDSB shares dropped by -4.07% in over the last four-week period, additionally plugging by 322.39% over the last 6 months not to mention a drop of -50.44% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PDSB stock in for the last two-week period is set at 55.48, with the RSI for the last a single of trading hit 67.29, and the three-weeks RSI is set at 53.92 for PDS Biotechnology Corporation [PDSB]. The present Moving Average for the last 50 days of trading for this stock 2.98, while it was recorded at 2.55 for the last single week of trading, and 1.93 for the last 200 days.

Return on Total Capital for PDSB is now -74.68, given the latest momentum, and Return on Invested Capital for the company is -33.70. Return on Equity for this stock declined to -33.70, with Return on Assets sitting at -27.60.

Reflecting on the efficiency of the workforce at the company, PDS Biotechnology Corporation [PDSB] managed to generate an average of -$349,930 per employee.PDS Biotechnology Corporations liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 7.70.

With the latest financial reports released by the company, PDS Biotechnology Corporation posted -1.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.82/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -34.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PDSB.

There are presently around $5 million, or 8.00% of PDSB stock, in the hands of institutional investors. The top three institutional holders of PDSB stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 622,672, which is approximately 101.108% of the companys market cap and around 35.92% of the total institutional ownership; FEDERATED HERMES, INC., holding 384,000 shares of the stock with an approximate value of $1.09 million in PDSB stocks shares; and FIRST MANHATTAN CO, currently with $0.42 million in PDSB stock with ownership of nearly 0% of the companys market capitalization.

Positions in PDS Biotechnology Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 10 institutional holders increased their position in PDS Biotechnology Corporation [NASDAQ:PDSB] by around 462,139 shares. Additionally, 12 investors decreased positions by around 392,147 shares, while 14 investors held positions by with 848,804 shares. The mentioned changes placed institutional holdings at 1,703,090 shares, according to the latest SEC report filing. PDSB stock had 6 new institutional investments in for a total of 72,701 shares, while 9 institutional investors sold positions of 372,040 shares during the same period.

Follow this link:
PDS Biotechnology Corporation [PDSB] gain 6.79% so far this year. What now? - The DBT News

The 94 rating InvestorsObserver gives to Aquestive Therapeutics Inc (AQST) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 100 percent of stocks in the Biotechnology industry, AQSTs 94 overall rating means the stock scores better than 94 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 94 would rank higher than 94 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Aquestive Therapeutics Inc (AQST) stock is trading at $8.78 as of 3:10 PM on Monday, Sep 21, a decline of -$0.27, or -2.98% from the previous closing price of $9.05. The stock has traded between $8.52 and $9.09 so far today. Volume today is 945,661 compared to average volume of 1,159,181.

Click Here to get the full Stock Score Report on Aquestive Therapeutics Inc (AQST) Stock.

View original post here:
Is Aquestive Therapeutics Inc (AQST) the Top Pick in the Biotechnology Industry? - InvestorsObserver

MacroGenics Inc (MGNX) is near the top in its industry group according to InvestorsObserver. MGNX gets an overall rating of 64. That means it scores higher than 64 percent of stocks. MacroGenics Inc gets a 75 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

MacroGenics Inc (MGNX) stock is trading at $27.70 as of 1:10 PM on Monday, Sep 21, a decline of -$3.90, or -12.34% from the previous closing price of $31.60. The stock has traded between $27.45 and $30.56 so far today. Volume today is 456,042 compared to average volume of 558,970.

Click Here to get the full Stock Score Report on MacroGenics Inc (MGNX) Stock.

Originally posted here:
Is MacroGenics Inc (MGNX) a Winner in the Biotechnology Industry? - InvestorsObserver

Time seemed to pause for Willie Hawes.

How do you measure time?

By minutes?By moments? By memories?

If you go by years, Willie Hawes has us all beat.

Somewhere in themid-1980s, The Augusta Chronicle's reporters discovered Hawes, a retired farmer living near Appling.

He was a quiet man, beloved by a large family that called him "Papa," unremarkable perhaps, except that he was then 113 years old and would live to be 120.

He didn't have a birth certificate. Georgia didn't begin to keep such records until 1919 when he was 47. But he did appear in a church census in his native Lincoln County, which recorded his arrival as Jan. 15, 1872.

Think about that.

In January 1872, Ulysses S. Grant had not finished his first term as president. The flag of the United States only had 37 stars and George Armstrong Custer still had his hair.

After discovery of Hawes' singular longevity, a series of reporters would stop by each January for an update on his health, a wrapup of his birthday celebration and any possible insights into how one lives more than a century.

Despite growing deafness and failing sight, Hawes was kind and gracious.He preached the virtues of common sense and "eating the right foods."

His family would laugh and point out his appetite was legendary.

He liked to eat corn, spaghetti, fried chicken, turnip greens, pecan pie and a number of "stick-to-your-ribs" menu items,they'd say.

At one birthday banquet, he finished off potato salad, chitterlings, cabbage and cornbread,and then had yellow cake with white icing for dessert. They didn't bother with candles on his cakes, either, because by thetime you got all 100-plus lighted, some had melted down.

Yes, he ate well much of his life, but he also worked hard,usually with a mule and a plow. He did this a long time, explaining, "that way you know what you're eating."

He farmed in Lincoln County until 1924 when a flood prompted amove to Columbia County,where he continued to farm into his 80s.

He was always a robust man, who decided to demonstrate his agility at age 100 by leaping onto the hood of a grandson's car. His children and grandchildren loved to hear him tell stories, but also knew him as a strict disciplinarian who "only had to whip you once."

By the time Hawes reached 118, NBC's well-known weatherman Willard Scott of the Today Show began to salute his birthdays in national broadcasts.

When Hawes turned 120 in 1992, the newspaper sought out a doctor, who called him "an extraordinary physical specimen," and attributed his long life to family genetics, a good heart, low cholesterol, hard work and a healthy diet.

That was the last reporter visit.

Willie Hawes died April 26, 1992. He was 120 years, 3 months and 11 days old.He was buried in the Second Mount Carmel Baptist Church cemetery and his funeralwas no doubt well attended.

Survivors included three daughters, one son, an adopted son, five stepsons, three stepdaughters, a brother, 46 grandchildren, 113 great-grandchildren and 84 great-great grandchildren.

Visit link:
The Way We Were: Applings Willie Hawes, a legend of longevity - The Augusta Chronicle

Think of bitter melon (also commonly referred to as "goya") as a distant cousin to your cantaloupe or honeydew. In fact, it's technically part of the gourd family and doesn't really look like a melon at all: "It looks like a warty cucumber," says Buettner.

Aesthetics aside, bitter melon has some pretty impressive nutritional benefits. "Packed with phytonutrients and vitamins, it's a good source of vitamins C, A, and E. It also is rich in B vitamins, including folate and B2. Additionally, it has potassium, iron, magnesium, and zinc. If that's not enough, it contains high levels of antioxidants," writes registered dietitian Mascha Davis, R.D., MPH, about the benefits of bitter melon.

Specifically, Buettner notes that the melon can be beneficial for diabetes and prediabetes: "There's three compounds in it that help lower blood sugar," he explains. These compounds (called chantarin, polypeptide-p, and vicine, in case you're curious) have been shown to act similar to insulin when they're ingested in the body. Of course, much more research is necessary before we can consider bitter melon a helpful treatment for the chronic condition, but the blood sugar benefits (and Buettner's anthropological evidence for longevity) shouldn't be ignored.

Original post:
A Longevity Expert On The Weird Fruit That's A+ For Blood Sugar Balance - mindbodygreen.com

Imagine for a minute that you want to help animals, want to preserve history or serve as a volunteer firefighter or help veterans in Kerr County. So, the best possible solution is to ask the Kerr County Commissioners Court to help fund those endeavors.

If those areas interest you, just be warned that you better find alternative funding, because the Kerr County Commissioners cant seem to commit when it comes to funding those things. Using the excuse that they were required statutorily to spend money on certain services, the commissioners held up funding for volunteer fire departments, veterans and the historical commission. After pressure from residents, especially veterans, the county delivered the money although less than what was previously given to the groups.

When it comes to funding for themselves, the county commissioners were pretty quick to give themselves a raise. Well, its not really a raise if you believe the county but its a longevity increase, which will be doled out to every member of the commissioners court.

This was part of the 2021 budget approved by the commissioners on Monday. The salary part of the budget was voted on separately and approved unanimously. So heres how this breaks down:

During their meeting, the commissioners made it clear that this was a requirement based on a previous action the court made to grant longevity increases for elected officials.

Moser said it was very important for people to understand that this was a longevity increase. The total amount of money the commissioners gave themselves adds up to about $3,500.

You can call it anything you want. You can say its required. But it is within this courts authority to take action to reverse this.

Sure, its great that they will give longevity increases to all county employees, but you dont have to give one to yourselves. Take one for the team, and bypass the raise.

This move speaks to the problem with the court on the subject of fiscal responsibility. By comparison, the city of Kerrville adopted a budget that essentially froze salaries and will leave some positions unfilled.

The citys top management, led by City Manager Mark McDaniel, all took voluntary pay cuts. Others in the city staff attempted to volunteer to take pay cuts to help the citys bottom line, but those overtures, while appreciated, were rejected by the City Council.

In turn, the city has vowed not to reduce essential services when it comes to its 2021 budget.

In contrast, in recent weeks, the county has made it clear to organizations, such as volunteer fire departments, that it no longer has the money to provide funding for those efforts and that they should seek funding through other sources.

The county went through an arduous exercise last year in saying it could no longer afford some of the animal control services it provides the community. The countys answer has been to solicit nonprofit groups, such as Kerrville Pets Alive, to handle the work they dont want to do or to fund.

Earlier this year, county officials discussed defunding the veterans service office, which plays an essential role in helping Kerr County veterans navigate the complex Veterans Affairs Administration, along with other services. That drew appropriate outrage from many members of the veterans community.

This last week, the county asked the Historical Commission to defend its budget requests, before approving a meager $4,500.

The coronavirus pandemic has hurt Kerr County economically, but the region appears to be doing better than others. The uncertainty that the virus brings economically shouldnt be discounted.

The fiscally prudent course of action would be to hold off on raises, especially for elected officials, and especially if it means preserving services that benefit residents.

Drafting a budget is one of the courts most important responsibilities. It is within their realm of authority to forgo these raises and instead direct that money to services that will benefit their constituents.

See the rest here:
OPINION: Elected officials salary increase send the wrong message - dailytimes.com

Big Show recently chatted with WWE Now India and answered some fan questions about his career. You can view a video and some highlights of that chat here:

Big Show on his longevity for his career: Somebody said to that to me months ago. Big Show has been performing for four decades! I was just like, I had to take a breath and go, Wow. Okay. Yeah. Thats true. My approach has always been about being dependable and being universal. Everything cant be about yourself to be successful and to have a long career. Sure, you have to take the opportunities that youre given and make the most out of them, but also, its about supporting other talent and bringing other talent along. So for me, I think my willingness to try anything and my willingness to be dependable and my willingness to help others succeed is why Ive been around so long.

On if he wants to face Keith Lee: Keith has a ton of momentum behind him right now. I think hes a tremendous competitor. I think if there was an opportunity for me to step in the ring and help Keith on his journey in some way, shape or form, Id love to do. Plus, hes got a good chest for chopping.

Big Show on the best advice he got in the business: I would say one of the earlier pieces of advice I got was from the legendary Big Boss Man, Ray Traylor. I had been in the business about six months, maybe, and this is when I was with WCW. I was going into the gym as he was coming out and we talked for a bit. He was a super nice guy. He said, Kid, Im going to tell you something. Be nice to everyone and be humble on the way up because you meet the same people on the way down. And hes right because no one stays on top forever. That mountain top is always changing. So, if youre rude and a jerk on the way to the top, theres going to be no support for you when you have to step aside for someone else whenever that time comes. And thats strong advice for treating everyone else the way you want to be treated. That and Macho Man Randy Savage used to tell me all the time, Keep that credit card in your wallet, and dont try to run with the Jones. Save your money, kid. So, that was Macho Man all the time. I think Macho Man still had his tooth fair money. He was very frugal, extremely frugal.

On his plans after he retires from the ring: Knowing me, if I retire from WWE, competing in the ring, Ill still be involved somehow. Either helping young Superstars behind the scenes, or Ill roll into some kind of project that stays busy. Im a whats today, whats tomorrow kind of guy. I dont look into the past. You cant change the past. You can learn from your mistakes and try not to repeat them. But living in past glories or past accolades limits you from creating any new memorable moments. So, my attitude is always one of onward and upward. Whats today. Whats tomorrow. What are are going, what are doing? It will be something fast paced and something positive, for sure because I cant sit still.

If using any of the above quotes, please credit WWE Now India, with a h/t to 411mania.com for the transcription.

See the original post here:
Big Show on His Longevity: 'My Approach Has Always Been About Being Dependable and Universal' - 411mania.com

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the precision medicine software market and it is poised to grow by USD 882.65 mn during 2020-2024, progressing at a CAGR of about 11% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions:

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. F. Hoffmann-La Roche Ltd., Fabric Genomics Inc., Gene42 Inc., Human Longevity Inc., International Business Machines Corp., Koninklijke Philips NV, NantHealth Inc., Roper Technologies Inc., SOPHiA GENETICS SA, and Syapse Inc. are some of the major market participants. The benefits of precision medicine will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Precision Medicine Software Market 2020-2024: Segmentation

Precision Medicine Software Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40844

Precision Medicine Software Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The precision medicine software market report covers the following areas:

This study identifies the digitization of healthcare as one of the prime reasons driving the Precision Medicine Software Market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Precision Medicine Software Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY DELIVERY MODE

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

See the article here:
Precision Medicine Software Market- Roadmap for Recovery from COVID-19|Benefits Of Precision Medicine to Boost the Market Growth | Technavio -...

Ads

For my review of the latest Motorola Razrset for release this fall, I tested the updated foldable phone for 10 days in September. Occasionally when I opened or closed the phone, an onlooker would react with disbelief. One woman working behind the register of a coffee shops to-go window actually gathered her (masked and socially distanced) co-workers and asked me to show them how the Razr folded in half. When I demonstrated the screen folding like paper, her response was: That is amazing. Where do I get one?

And thts the mgic of foldble phones t their core. They seemingly do the impossible by letting you tke something rectngulr nd rigid nd fold it into something smller thn drink coster. Tht mgic comes from yers of design, testing nd revisions. And the engineers nd designers who worked on the upcoming Motorol Rzr know its nything but mgic to mke 6.2-inch phone fold in hlf.

But ll tht work cn be esily overshdowed. The review units of 2019s Smsung Glxy Foldrised the flg bout how folding screens would work in the rel world. A number of them hddefectsn>tht let dust or other prticles get underneth the screen nd wrek hvoc. Any concerns people hd bout folding displys were instntly mplified.

Then in Februry 2020 fter months of delys, Motorol relesed its Rzr (2019) with foldble screen nd CNETs video tem tested the displys durbility. My collegue Chris Prker used FoldBot nd ttempted to open nd close the phone 100,000 times. After 27,000 folds the Rzr (2019) wsnt ble to be tested further. Reflecting on tht test nd how SqureTrde modified its FoldBot to hndle the Rzrn>, Prker concluded:

Does [it] feel like durble, resilient phone tht will stnd up to extended rel-world use? To me it does.

These incidents might mke you wonder if foldble screens re durble. And if so, how do we know? Jeff Snow, generl mnger of innovtion products t Motorol, thinks its nturl to sk durbility questions bout foldble screens.

The new thing bout the phone is the fct tht the screen folds open nd you cn light it up, sid Snow. People re not used to phones with those folding screens. So the questions in their minds re, Is it going to lst? How mny times cn I ctully do tht ction?'

Motorol clims the screen on its upcoming, updted Rzr (2020) cn be folded 200,000 times. To give you n ide how mny times tht is, you could open nd close the phone 100 times dy for five yers nd still not hit tht number.

To show me how the compny determined nd tested the number of times the upcoming Rzrs screen could be folded, I visited lb t Motorol in Chicgo while wering msk nd socil distncing to meet Snow nd Tom Gitzinger, director nd principl engineer of innovtion nd rchitecture for Motorol. I got to see for myself how Motorol tests the screen on the upcoming Rzr.

In room tht looks like college blck box theter re number of lights ll focused on roughly 10-foot-wide mchine. There is cmer on tripod pointing t the mchine which gives the entire spce n odd television show vibe. On the top of the wist-high mchine on their bcks, re four Rzr (2020) phones. The mchine fully opens nd closes ll four phones t the sme time over nd over.

Throughout the design nd mnufcturing process, Motorol uses similr mchines to test the folds on the Rzr (2020). Unlike the Smsung Glxy Z Flip, which is designed to be opened to vriety of positions, the Rzr is built to either be fully open nd flt or completely closed. And unlike the Foldbot, Motorols mchine uses wire to open the Rzrs perfectly flt nd n rm to close them shut. The wire is thin enough to nestle between the two hlves of the phone when its closed.

To recrete those 200,000 folds in less thn five yers time, the mchine fully opens nd closes the phones once every 4 seconds. There is clming qulity to hering four phones shut closed every 4 seconds. Its like soft-sounding metronome. It tkes Motorol 10 dys to fold ech phone 200,000 times with this mchine.

Over the pst six months Motorol reched out to people who own the Rzr (2019) to lern how they use the phone. According to Snow, Rzr owners open nd close their phones on verge 40 times dy. And super users (the 99th percentile), verge 100 times dy. Hence, Motorol designed the upcoming Rzr (2020) to hndle 200,000 folds.

Were not chnging the prmeters of testing, sid Snow. But we wnt to mke sure tht were understnding people nd exceeding their expecttions.

The phones zero gp design, screen nd hinge llows the Rzr to chieve high level of screen durbility. The upcoming Rzr (2020) lrgely uses tht sme design s the Rzr (2019) lbeit with tweks. In fct, if you wnt to lern more bout the hinge tke look below t video I mde lst yer bout its design nd how it llows the Rzr (2019) to fold flt.

The screen itself is mde of five different lyers nd then spryed with hrd coting. When the lyers re combined the screen hs thickness of 355 microns (3.5 millimeters). To give you sense of how thin tht is, the Motorol Edge Plusn> uses similr OLED pnel stck for the curved edges of its screen which is three times the thickness of the Rzrs disply stck.

And its not just the disply tht is folding in hlf. There re number of connections including the four 5G ntenns tht hve to trverse the hinge. And like other foldble phones, the bttery in the Rzr is ctully two btteries, one on ech end. Not only does this help with blnce, but it dds nother level of complexity s both hve to connect through the Rzrs hinge mechnism.

When I reviewed the Rzr (2019) in Februry, it suffered from squek/crek. It ws like muffled crunching sound but loud. During my time with the upcoming Rzr (2020), the squek/crek ws mostly bsent until Fridy my eighth dy with the phone. And when it did squek, it ws quieter sound, more like breking in pir of new lether boots. Gitzinger explined the noise by compring it to bg of potto chips.

You cnt possibly open potto chip bg without mking noise. Its super thin. Its lot more crunchy nd crinkly thn something like this [the foldble disply]. But the sme principle pplies, sid Gitzinger. Youve got this big, significnt surfce tht moves round, nd its pushing ir tht cretes some of the noises. We were ble to eliminte other noises by putting in some old friction dhesives nd tpes nd surfces to enble everything to slide pst one nother bit more esily.

I sked friend how they felt bout the squek/crek on the upcoming Rzr (2020) nd they sid it didnt bother them. I guess when it comes to screen notches, foldble screen creses nd now foldble phone squeks, some people will get used to these things while others will be nnoyed.

With the improvements mde, Motorol is confident bout the upcoming Rzrs durbility. In fct, the compny runs 40 different lb checks to test both the design nd qulity of the phone during development nd mnufcturing.

Tht sid, the true indictor for how durble the screen on the Rzr (2020) or ny foldble phone is time. Until then, just like mgic, foldble phones require bit of fith.

For more detils mke sure to check out my review of the upcoming Motorol Rzrn>.

Ads

View original post here:
Worried regarding foldable phones longevity? Heres just how Motorola evaluates the Razr joint - Entertainment Overdose

Singapore has launched the LumiHealth app with Apple, in an innovative move to help improve health and wellness outcomes. The collaboration was announced today as part of the countrys Smart Nation initiative. A national effort to leverage technology to deliver benefits to its citizens and businesses.

LumiHealth will use technology and behavioral insights to encourage Singaporeans to maintain healthy and complete wellness challenges through their Apple Watch and iPhone. The app was created by a team of physicians and public health experts.

According to Bloomberg, as part of the scheme, Singapore residents will be able to earn as much as S$380 ($280) in rewards and vouchers by completing goals and tasks set within the app. Goals can be accomplished by walking or doing other exercises like swimming or yoga. The LumiHealth app will offer personalized coaching and reminders for health screenings and immunizations. Wellness challenges will nudge users toward making better food choices and improving sleep habits.

The LumiHealth program is voluntary. While the issue of privacy of data is always debated when an initiative of this scale is initiated, Apple assured the media the app has been designed with user privacy and security at its core. All user data will be encrypted and none will be sold or shared for marketing purposes.

The Singapore government is known for its innovative approach to health and technology. Singapores Deputy Prime Minister Heng Swee Keat told media, Even as all of us around the world are dealing with the challenges of COVID-19, we must keep investing in our future. And there is no better investment than in our own personal health.

Singapore has one of the worlds leading healthcare systems, and we are thrilled to be partnering with them to incorporate Apple Watch and LumiHealth into their holistic approach to well-being, said Jeff Williams, Apples chief operating officer. Apple Watch has already helped millions of our customers manage their activity levels to improve their health, and we look forward to applying our expertise here in the same privacy-friendly way that distinguishes all Apple products and services.

LumiHealth is available in the App Store for pre-order now, and the two-year program will be offered from late October 2020.

The city-state was among the first to roll out a contact-tracing app to help combat the coronavirus pandemic this year. It is expanding that effort by distributing tokens that will allow residents to enter selected venues, in an effort that may pave the way for larger gatherings.

Technology is shaping our future and longevity. Click here to read more.

Go here to see the original:
Singapore and Apple Launch LumiHealth App To Boost Wellness - Longevity LIVE

Anderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., et al (2012). Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science translational medicine,4(151), 151ra125. https://doi.org/10.1126/scitranslmed.3004006

Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., et al. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England journal of medicine,367(5), 399410. https://doi.org/10.1056/NEJMoa1108524

Mizushima D et al.(2020).Prophylactic effect of PrEP against HBV infection among MSM.Conference on Retroviruses and Opportunistic Infections, abstract 1025.

Spinelli, M. A., Glidden, D. V., Anderson, P. L., Gandhi, M., et al. (2019). Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. AIDS research and human retroviruses,35(9), 788793. https://doi.org/10.1089/AID.2018.0297

Volk, J., Marcus, J.L., Phengrasamy, T., Blechinger, D., et al. (2015). No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting,Clinical Infectious Diseases, Volume 61, Issue 10, Pages 16011603,https://doi.org/10.1093/cid/civ778

Continue reading here:
PrEP: Everything Men Need To Know About Pre-Exposure Prophylaxis - Longevity LIVE

Military officials: Live mortar round found in Carter Co. backyard 'could be anywhere from WWII to the Vietnam War era'News / 23 mins ago

'We're just kind of in different places right now': V-T series between Bearcats and Vikings halted through 2022News / 48 mins ago

'We're just kind of in different places right now': V-T series between Bearcats and Vikings halted through 2022News / 1 hour ago

HMG Health Matters: Flu season and COVID-19 collideNews / 1 hour ago

JCPD says case of woman falling five stories downtown now a 'medical investigation'News / 1 hour ago

Two anonymous donors gift former Ashley Academy building to Jeremiah SchoolNews / 1 hour ago

Carter County Mayor Rusty Barnett passes away MondayNews / 6 hours ago

JCPD: Investigation underway after woman falls from fifth story downtownNews / 9 hours ago

Superintendent: Tazewell Co. Public Schools employee tests positive for COVID-19News / 11 hours ago

Sen. Lamar Alexander announces stance on US Supreme Court nominationNews / 11 hours ago

Replacing Ginsburg: what comes next as nomination, Nov. election loom?News / 11 hours ago

100-year-old Boones Creek woman reveals her tips for longevityNews / 20 hours ago

View post:
Military officials: Live mortar round found in Carter Co. backyard 'could be anywhere from WWII to the Vietnam War era' - WJHL-TV News Channel 11

Image credit: Merakist on Unsplash

SEO has become a leading digital marketing strategy

Consider SEO, for instance. Search engine optimisation is all about giving businesses and entrepreneurs alike a way to measure success online through organic growth and rising prominent presents in online search engines around the globe. SEO has been played with its fair share of criticism and controversy over the years, however, for the most part SEO has more than pregnant it's value and today it is one of the leading digital marketing strategies there is. The success and longevity it is measured through SEO marketing is really about approaching SEO from a strong perspective as well as one that is coming hand in hand with a strong and structured stance.

The powerful potential of local SEO strategies

And then there is local SEO. What is local SEO?, you may ask. In short, local SEO is essentially a digital marketing strategy that allows local businesses to become discoverable and search engines on a local basis. This is focused on different SEO factors such as link building and on-page optimisation and the goal is always to get a website to the front page of Google for elephant searches within a local dermographic. Local SEO essentially takes SEO to the next level by giving websites and web pages a chance to move up in the ranks on search engines for keywords that are on a local standard and that genuinely positively impact the overall approach to SEO.

Why local SEO has so much to offer modern businesses

At the end of the day, SEO is incredibly powerful and local SEO is even more so. More than anything else, local SEO now has so much to offer modern businesses because it effectively gives you the momentum and the potential to rise up in search engines and an organic level and in ways that are entirely interpretive and incomprehensible. Local SEO is well and truly on the rise and while SEO itself is a leading digital marketing strategy today, there is no reason at all to think that local SEO is not going to rise to the same global levels of longevity and success in the coming years and beyond.

Visit link:
Embracing the powerful potential of local SEO - Bizcommunity.com